Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (November 2026)
23 slides from Proteomics International Laboratories's investor presentation, Nov 4, 2026
Slide 1: Investor Webinar: Disciplined Path to Commercial Success
Proteomics International Laboratories Ltd rsonal use only Investor Webinar Disciplined Path to Commercial Success 4 November 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation has been prepared by, and is the sole responsibility of Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ) and is dated 4 November 2026. The Company is under no obligation to update or keep the information r
Slide 3: Executive Summary: Disciplined Path to Commercial Success
EXECUTIVE SUMMARY Disciplined Path to Commercial Success Proteomics International has secured Healius as exclusive distributor and begun the national rollout of Promarker D and Eso. Next, we are rsonal use only targeting the Endo launch in early 2027, the appointment of a US distributor and advancin
Slide 4: About Us
COMPANY OVERVIEW About Us rsonal use only Proteomics International (ASX: PIQ) develops proprietary blood tests for disease prediction and diagnosis. We deliver laboratory testing and clinical reporting, while distribution partners provide market access to clinicians and patients. Target Unmet Levera
Slide 5: Innovation Portfolio – Four Tests
PORTFOLIO Innovation Portfolio – Four Tests rsonal use only Proteomics International provides a suite of four prognostic and diagnostic tests targeting specific clinical areas of unmet need. Our priority is to validate and commercialise these tests before developing new tests for other medical condi
Slide 6: Innovation Portfolio – Three Promarker Tests
PORTFOLIO Innovation Portfolio – Three Promarker Tests rsonal use only The Promarker Portfolio tests address distinct clinical pathways, supporting earlier risk identification, more targeted referral and more efficient use of healthcare resources. Promarker D Promarker Eso Promarker Endo Clinical Id
Slide 7: Innovation Portfolio – Market Potential
MARKET POTENTIAL Innovation Portfolio – Market Potential rsonal use only Market opportunities for the three main tests were evaluated across Australia and the United States. The analysis indicated a sizeable serviceable obtainable market with significant growth potential. Australian patient pricing
Slide 8: Healius Distribution Partnership
DISTRIBUTION MODEL Healius Distribution Partnership rsonal use only Exclusive Australian pathology distribution for the Promarker® portfolio. Healius provides national market access through its collection network and referrer relationships, while Proteomics delivers testing and clinical reporting. S
Slide 9: Execution Plan – The Next Years
STRATEGIC ROADMAP Execution Plan – The Next 3 Years rsonal use only The strategic roadmap outlines the 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value. RESET ACCESS ADVANCE ACC
Slide 10: Share Purchase Plan
CAPITAL RAISE Share Purchase Plan rsonal use only An opportunity for eligible shareholders to participate in Proteomics’ growth. COMMERCIAL PROGRESS OFFER PRICE PER NEW SHARE Healius partnership National distribution partnership secured Australian rollout A$0.10 Promarker D and Promarker Eso rollout
Slide 11: Sources and Uses of Funds
CAPITAL RAISE Sources and Uses of Funds rsonal use only SOURCES OF FUNDS USES OF FUNDS A$ million A$9.1m Research and product development 2.0 Clinical evidence and reimbursement 1.6 Cash at 30 September 2026 1.8 Commercial execution and market access 1.6 R&D tax refund received 2.0 Laboratory operat
Slide 12: Appendix
Proteomics International Laboratories Ltd rsonal use only APPENDIX 4 November 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Slide 13: Board of Directors
LEADERSHIP Board of Directors rsonal use only Dr James Williams Non- David Morris Aaron Brinkworth Paul House Vicki Robinson Executive Chair CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director PhD, MBA, BSc (Hons) GAICD BBus, BAppSc, GAICD BHIthSc, GAICD BEng
Slide 14: Science of Proteomics
PLATFORM Science of Proteomics rsonal use only Genes carry the instructions. Proteins reveal how those instructions play out in health and disease. Translating that insight into reliable diagnostic and prognostic tests requires precision, standardisation and deep technical expertise. Genes Provide P
Slide 15: Strategic Framework for Execution
ENTERPRISE PRIORITIES Strategic Framework for Execution rsonal use only Enterprise objectives create a clear framework aligning strategy with execution, focusing on areas of commercial execution, innovation, operations, and organisational capabilities to deliver lasting value for patients, partners,
Slide 16: Patient Care Ecosystem
CLINICAL PATHWAY Patient Care Ecosystem rsonal use only The patient journey involves clear roles for patients, clinicians, distributors, and labs. Proteomics International handles development and testing, while partners manage market access, ensuring accountability and quality from collection to res
Slide 17: Promarker D – Chronic Kidney Disease
PRODUCT OVERVIEW Promarker D – Chronic Kidney Disease rsonal use only Prognostic blood test to predict the risk of diabetes related chronic kidney disease up to 4 years before symptoms appear, enabling earlier clinical intervention and ongoing monitoring. Clinical Value Market Opportunity Key Action
Slide 18: Patient Journey: Promarker D
PATIENT JOURNEY Promarker D – Chronic Kidney Disease rsonal use only Promarker D enables a shift from reactive CKD treatment to proactive risk-based care, identifying risk earlier, guiding targeted intervention, and helping reduce late-stage cost burden. SYMPTOMS EVALUATION MANAGEMENT Risk Becomes V
Slide 19: Promarker Eso – Oesophageal Cancer
PRODUCT OVERVIEW Promarker Eso – Oesophageal Cancer rsonal use only Minimally invasive diagnostic blood test for patients with chronic reflux that detects specific protein changes to rule out oesophageal adenocarcinoma, thus reducing the need for invasive surveillance endoscopy procedures. Clinical
Slide 20: Patient Journey: Promarker Eso
PATIENT JOURNEY Promarker Eso – Oesophageal Cancer rsonal use only Promarker Eso could shift oesophageal cancer risk assessment from procedure-led surveillance to a faster, lower-burden blood-test triage pathway. SYMPTOMS EVALUATION MANAGEMENT Measurable Risk Insight Earlier Risk Stratification Targ
Slide 21: Promarker Endo – Endometriosis
PRODUCT OVERVIEW Promarker Endo – Endometriosis rsonal use only Diagnostic blood test for patients with symptoms suggestive of endometriosis, thus reducing the extensive delays in diagnosis and management. Promarker Endo test has now been refined and independently validated. Clinical Value Market Op
Slide 22: Patient Journey: Promarker Endo
PATIENT JOURNEY Promarker Endo – Endometriosis rsonal use only Promarker Endo could shorten the path from symptoms to clarity, using a blood-test risk triage to support earlier referral and more targeted care. Promarker Endo test has now been refined and independently validated. SYMPTOMS EVALUATION
Slide 23: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd rsonal use only ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Proteomics International Laboratories — Investor Presentation (November 2026) on 6ix